NASDAQ:CBPO - China Biologic Products Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $90.31 -0.74 (-0.81 %) (As of 05/24/2019 06:54 AM ET)Previous Close$91.05Today's Range$90.00 - $91.0052-Week Range$60.08 - $107.44Volume183,561 shsAverage Volume225,529 shsMarket Capitalization$3.55 billionP/E Ratio22.47Dividend YieldN/ABeta1.28 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China. Receive CBPO News and Ratings via Email Sign-up to receive the latest news and ratings for CBPO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBPO Previous Symbol CUSIPN/A CIK1369868 Webhttp://www.chinabiologic.com/ Phone86-10-6598-3111Debt Debt-to-Equity RatioN/A Current Ratio12.62 Quick Ratio10.30Price-To-Earnings Trailing P/E Ratio22.47 Forward P/E Ratio23.34 P/E Growth4.74 Sales & Book Value Annual Sales$466.88 million Price / Sales7.61 Cash Flow$5.0312 per share Price / Cash Flow17.95 Book Value$47.84 per share Price / Book1.89Profitability EPS (Most Recent Fiscal Year)$4.02 Net Income$128.06 million Net Margins27.71% Return on Equity8.81% Return on Assets8.04%Miscellaneous Employees2,187 Outstanding Shares39,362,000Market Cap$3.55 billion Next Earnings Date8/2/2019 (Estimated) OptionableOptionable China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions What is China Biologic Products' stock symbol? China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO." How were China Biologic Products' earnings last quarter? China Biologic Products Holdings Inc (NASDAQ:CBPO) announced its quarterly earnings results on Friday, May, 10th. The biopharmaceutical company reported $1.11 EPS for the quarter, beating analysts' consensus estimates of $0.99 by $0.12. The biopharmaceutical company earned $129.78 million during the quarter, compared to analyst estimates of $119.50 million. China Biologic Products had a return on equity of 8.81% and a net margin of 27.71%. During the same period in the prior year, the company earned $1.21 earnings per share. View China Biologic Products' Earnings History. When is China Biologic Products' next earnings date? China Biologic Products is scheduled to release their next quarterly earnings announcement on Friday, August 2nd 2019. View Earnings Estimates for China Biologic Products. What price target have analysts set for CBPO? 3 brokers have issued twelve-month price targets for China Biologic Products' shares. Their predictions range from $62.00 to $88.00. On average, they anticipate China Biologic Products' share price to reach $78.00 in the next twelve months. This suggests that the stock has a possible downside of 13.6%. View Analyst Price Targets for China Biologic Products. What is the consensus analysts' recommendation for China Biologic Products? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for China Biologic Products in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for China Biologic Products. Has China Biologic Products been receiving favorable news coverage? News articles about CBPO stock have trended negative recently, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. China Biologic Products earned a media sentiment score of -2.7 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the next several days. Are investors shorting China Biologic Products? China Biologic Products saw a increase in short interest during the month of April. As of April 15th, there was short interest totalling 1,819,122 shares, an increase of 46.1% from the March 29th total of 1,245,080 shares. Based on an average daily volume of 378,996 shares, the short-interest ratio is currently 4.8 days. Approximately 8.2% of the company's stock are sold short. View China Biologic Products' Current Options Chain. Who are some of China Biologic Products' key competitors? Some companies that are related to China Biologic Products include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), BIO-TECHNE (TECH), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP) and Denali Therapeutics (DNLI). What other stocks do shareholders of China Biologic Products own? Based on aggregate information from My MarketBeat watchlists, some companies that other China Biologic Products investors own include Lexicon Pharmaceuticals (LXRX), Sarepta Therapeutics (SRPT), The Carlyle Group (CG), Gilead Sciences (GILD), Biogen (BIIB), GSI Technology (GSIT), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), Amgen (AMGN) and NVIDIA (NVDA). Who are China Biologic Products' key executives? China Biologic Products' management team includes the folowing people: Mr. Ming Yang, Chief Financial Officer (Age 47)Mr. Ming Yin, Sr. VP (Age 41)Ms. Zhijing Liu, Corp. VP (Age 65)Mr. Gang Yang, Corp. VP & GM of Guizhou Taibang (Age 54)Dr. Bing Li Ph.D., CEO & Director (Age 51) Who are China Biologic Products' major shareholders? China Biologic Products' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Hsbc Holdings PLC (3.64%), FIL Ltd (1.32%), Greenwoods Asset Management Ltd (1.22%), FMR LLC (1.07%), BlackRock Inc. (1.06%) and Maso Capital Partners Ltd (0.42%). View Institutional Ownership Trends for China Biologic Products. Which institutional investors are selling China Biologic Products stock? CBPO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Macquarie Group Ltd., Myriad Asset Management Ltd., Wasatch Advisors Inc., BlackRock Inc., Ossiam, TT International and Parametric Portfolio Associates LLC. View Insider Buying and Selling for China Biologic Products. Which institutional investors are buying China Biologic Products stock? CBPO stock was purchased by a variety of institutional investors in the last quarter, including Greenwoods Asset Management Ltd, Nikko Asset Management Americas Inc., Dalton Investments LLC, Goldman Sachs Group Inc., Renaissance Technologies LLC, Hsbc Holdings PLC, FIL Ltd and Maso Capital Partners Ltd. View Insider Buying and Selling for China Biologic Products. How do I buy shares of China Biologic Products? Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is China Biologic Products' stock price today? One share of CBPO stock can currently be purchased for approximately $90.31. How big of a company is China Biologic Products? China Biologic Products has a market capitalization of $3.55 billion and generates $466.88 million in revenue each year. The biopharmaceutical company earns $128.06 million in net income (profit) each year or $4.02 on an earnings per share basis. China Biologic Products employs 2,187 workers across the globe. What is China Biologic Products' official website? The official website for China Biologic Products is http://www.chinabiologic.com/. How can I contact China Biologic Products? China Biologic Products' mailing address is 18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected] MarketBeat Community Rating for China Biologic Products (NASDAQ CBPO)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 301 (Vote Outperform)Underperform Votes: 383 (Vote Underperform)Total Votes: 684MarketBeat's community ratings are surveys of what our community members think about China Biologic Products and other stocks. Vote "Outperform" if you believe CBPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBPO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Asset Allocation Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.